相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
F. Cognetti et al.
ANNALS OF ONCOLOGY (2012)
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy
Nagahide Matsumura et al.
BJU INTERNATIONAL (2011)
Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer
Atsunari Kawashima et al.
CLINICAL CANCER RESEARCH (2011)
EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 AS PREDICTIVE MARKER FOR NASOPHARYNGEAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY
Jong-Mu Sun et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status
Walter M. Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
Gareth Griffiths
JOURNAL OF CLINICAL ONCOLOGY (2011)
Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
Kyoung Ha Kim et al.
APMIS (2010)
MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy
Andreas-Claudius Hoffmann et al.
NEOPLASIA (2010)
Bladder Cancer: Narrowing the Gap Between Evidence and Practice
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy
In Gyu Hwang et al.
CANCER (2008)
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base
Kevin A. David et al.
JOURNAL OF UROLOGY (2007)
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2007)
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
P. Ceppi et al.
ANNALS OF ONCOLOGY (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
Ken A. Olaussen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Adjuvant chemotherapy in muscle-invasive bladder carcinoma - A pooled analysis from phase III studies
EM Ruggeri et al.
CANCER (2006)
Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data
AV Bono et al.
EUROPEAN UROLOGY (2005)
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
GR Simon et al.
CHEST (2005)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
HB Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic cystectomy trial 2
A Sherif et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2002)
分享论文
